The DOI matches its Crossref record.
Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response
Abstract
Systemic lupus erythematosus is characterized by B cell production of pathogenic autoantibodies dependent upon cooperation from CD4+ Th cells. The interaction between CD40 on B cells and CD40 ligand (CD40L) on Th cells is necessary for normal thymus-dependent Ab production. An anti-murine CD40L mAb blocks binding of CD40L to CD40 and prevents primary and secondary immune responses to thymus-dependent Ags. In this study, New Zealand Black x New Zealand White lupus-prone mice treated with this anti-CD40L Ab from ages 4 to 10 mo had reduced anti-DNA autoantibody production and renal disease and significantly prolonged survival compared with control mice. Pathologic examination verified the absence of significant renal damage or immune deposition in responding mice. Mice that responded to treatment did not develop an Ab response to the administered Ab. Long-term survivors mounted a substantial Ab response to keyhole limpet hemocyanin after completion of anti-CD40L Ab treatment, suggesting that some of the immunosuppressive effects of the Ab may be reversible. These results suggest a human form of this Ab may have therapeutic utility in human systemic lupus erythematosus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
BAFF and APRIL: A Tutorial on B Cell Survival
Mackay, F., Schneider, P., Rennert, P., & Browning, J. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141152 · Cited by 1,007
Hahn, B. H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805073381906 · Cited by 682
Uncoupling of Immune Complex Formation and Kidney Damage in Autoimmune Glomerulonephritis
Clynes, R., Dumitru, C., & Ravetch, J. V. (1998) · Science · doi:10.1126/science.279.5353.1052 · Cited by 625
Boumpas, D. T., Furie, R., Manzi, S., Illei, G. G., Wallace, D. J., Balow, J. E., Vaishnaw, A., & on behalf of the BG9588 Lupus Nephritis Trial Group (2003) · Arthritis & Rheumatism · doi:10.1002/art.10856 · Cited by 618
Kenyon, N. S., Chatzipetrou, M., Masetti, M., Ranuncoli, A., Oliveira, M., Wagner, J. L., Kirk, A. D., Harlan, D. M., Burkly, L. C., & Ricordi, C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.8132 · Cited by 415
Trambley, J., Bingaman, A. W., Lin, A., Elwood, E. T., Waitze, S.-Y., Ha, J., Durham, M. M., Corbascio, M., Cowan, S. R., Pearson, T. C., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8082 · Cited by 356
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
Zhang, Q., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.017 · Cited by 296
Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases
Croft, M., & Siegel, R. M. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.22 · Cited by 288
T cells as therapeutic targets in SLE
Crispín, J. C., Kyttaris, V. C., Terhorst, C., & Tsokos, G. C. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.60 · Cited by 271
CD40 and autoimmunity: The dark side of a great activator
Peters, A. L., Stunz, L. L., & Bishop, G. A. (2009) · Seminars in Immunology · doi:10.1016/j.smim.2009.05.012 · Cited by 270
Tesch, G. H., Schwarting, A., Kinoshita, K., Lan, H. Y., Rollins, B. J., & Kelley, V. R. (1999) · Journal of Clinical Investigation · doi:10.1172/jci4876 · Cited by 266
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients
Sidiropoulos, P. I., & Boumpas, D. T. (2004) · Lupus · doi:10.1191/0961203304lu1032oa · Cited by 178
Anti-DNA autoantibodies and systemic lupus erythematosus
Blatt, N. B., & Glick, G. D. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00022-4 · Cited by 60
Metadata
- Authors
- Early, G. S., Zhao, W., & Burns, C. M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-10-01
- Volume
- 157
- Issue
- 7
- Pages
- 3159-3164
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1514664819
- Cited by
- 218
- References
- 0
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.